TY - JOUR
T1 - Trends and predictors of outcomes after surgery for hepatocellular carcinoma
T2 - A nationwide population-based study in Taiwan
AU - Chiu, C. C.
AU - Wang, J. J.
AU - Chen, Y. S.
AU - Chen, J. J.
AU - Tsai, T. C.
AU - Lai, C. C.
AU - Sun, D. P.
AU - Shi, H. Y.
N1 - Publisher Copyright:
© 2015 Elsevier Ltd.
PY - 2015/9/1
Y1 - 2015/9/1
N2 - Abstract Background Despite the huge and growing global burden of hepatocellular carcinoma (HCC), high-quality population-based studies of HCC prevalence and outcomes are scarce. Purpose To analyze trends and predictors of hospital resource utilization and mortality rates in a population of patients who had received HCC surgery. Patients and materials This population-based patient cohort study retrospectively analyzed 23,107 patients who had received surgical treatment for HCC from 1998 to 2009. Results The prevalence rate of surgical treatment in HCC patients significantly increased by 167.4% from 4.857 per 100,000 persons in 1998 to 12.989 per 100,000 persons in 2009 (P < 0.001). Age, gender, Deyo-Charlson co-morbidity index score, hospital volume, surgeon volume, digestive system disease, hepatitis type and liver cirrhosis were significantly associated with HCC surgical outcomes (P < 0.05). Over the 12-year period analyzed, the estimated mean hospital treatment cost increased 9.4% whereas mean length of stay (LOS) decreased 25.3%. The estimated mean overall survival time after HCC surgery was 40.9 months (SD 1.2 months), and the overall in-hospital 1-, 3-, and 5-year survival rates were 97.2%, 79.9%, 61.1%, and 54.6%, respectively. Conclusions These population-based data reveal that the prevalence of HCC has increased, especially in older patients. Additionally, hospital treatment costs for HCC have increased despite decreases in LOS. These analytical results should be applicable to most countries with relatively small populations. Additionally, healthcare providers and patients should recognize that attributes of both the patient and the hospital may affect outcomes.
AB - Abstract Background Despite the huge and growing global burden of hepatocellular carcinoma (HCC), high-quality population-based studies of HCC prevalence and outcomes are scarce. Purpose To analyze trends and predictors of hospital resource utilization and mortality rates in a population of patients who had received HCC surgery. Patients and materials This population-based patient cohort study retrospectively analyzed 23,107 patients who had received surgical treatment for HCC from 1998 to 2009. Results The prevalence rate of surgical treatment in HCC patients significantly increased by 167.4% from 4.857 per 100,000 persons in 1998 to 12.989 per 100,000 persons in 2009 (P < 0.001). Age, gender, Deyo-Charlson co-morbidity index score, hospital volume, surgeon volume, digestive system disease, hepatitis type and liver cirrhosis were significantly associated with HCC surgical outcomes (P < 0.05). Over the 12-year period analyzed, the estimated mean hospital treatment cost increased 9.4% whereas mean length of stay (LOS) decreased 25.3%. The estimated mean overall survival time after HCC surgery was 40.9 months (SD 1.2 months), and the overall in-hospital 1-, 3-, and 5-year survival rates were 97.2%, 79.9%, 61.1%, and 54.6%, respectively. Conclusions These population-based data reveal that the prevalence of HCC has increased, especially in older patients. Additionally, hospital treatment costs for HCC have increased despite decreases in LOS. These analytical results should be applicable to most countries with relatively small populations. Additionally, healthcare providers and patients should recognize that attributes of both the patient and the hospital may affect outcomes.
KW - Hepatocellular carcinoma
KW - Hospital resource utilization
KW - Mortality rate
KW - Predictors
KW - Trends
UR - http://www.scopus.com/inward/record.url?scp=84938748766&partnerID=8YFLogxK
U2 - 10.1016/j.ejso.2015.04.023
DO - 10.1016/j.ejso.2015.04.023
M3 - 文章
C2 - 26048295
AN - SCOPUS:84938748766
SN - 0748-7983
VL - 41
SP - 1170
EP - 1178
JO - European Journal of Surgical Oncology
JF - European Journal of Surgical Oncology
IS - 9
M1 - 4060
ER -